Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.30 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3068836 | 1.00 | HTR1A (0.34) | HTR1AHTR7PTPN5PTPN2 | |
| SCHEMBL3070901 | 0.99 | HTR1A (0.34) | HTR1AHTR7 | |
| SCHEMBL3079843 | 0.90 | HTR1A (0.32) | HTR1AHTR7 | |
| SCHEMBL3068131 | 0.90 | HTR1A (0.32) | HTR1AHTR7 | |
| SCHEMBL3062491 | 0.89 | HTR1A (0.31) | HTR1AHTR7 | |
| SCHEMBL3069545 | 0.89 | HTR1A (0.31) | HTR1AHTR7 | |
| SCHEMBL3066395 | 0.89 | HTR1A (0.32) | HTR1AHTR7 | |
| SCHEMBL3075047 | 0.88 | HTR1A (0.32) | HTR1AHTR7 | |
| SCHEMBL3075553 | 0.86 | — | — | |
| SCHEMBL3064934 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299287-B2 | Metallocene compounds, catalysts comprising them, process for producing an olefin polymer by use of the catalysts, and olefin homo- and copolymers | Lammus Novolen Technology GmbH (DE) | 2012-10-30 | — | — | US | claimed |
| US-20100267907-A1 | METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO-AND COPOLYMERS | LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) | 2010-10-21 | — | — | US | claimed |
| US-8507706-B2 | Metallocene compounds, catalysts comprising them, process for producing an olefin polymer by use of the catalysts, and olefin homo- and copolymers | LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) | 2013-08-13 | — | — | US | disclosed |
| US-20120329964-A1 | METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS | LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) | 2012-12-27 | — | — | US | disclosed |
| US-8299287-B2 | Metallocene compounds, catalysts comprising them, process for producing an olefin polymer by use of the catalysts, and olefin homo- and copolymers | Lammus Novolen Technology GmbH (DE) | 2012-10-30 | — | — | US | disclosed |
| US-20100267907-A1 | METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO-AND COPOLYMERS | LUMMUS NOVOLEN TECHNOLOGY GMBH (DE) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329964-A1 | METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO- AND COPOLYMERS | PIN1, PCNA, OPRM1 | HTR1A 113/4885HTR7 455/4885PTPN5 4565/4885 |
| US-20100267907-A1 | METALLOCENE COMPOUNDS, CATALYSTS COMPRISING THEM, PROCESS FOR PRODUCING AN OLEFIN POLYMER BY USE OF THE CATALYSTS, AND OLEFIN HOMO-AND COPOLYMERS | PIN1, PCNA, OPRM1 | HTR1A 113/4885HTR7 455/4885PTPN5 4565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.